In vivo effects of partial phosphorothioated AT1 receptor antisense oligonucleotides in spontaneously hypertensive and normotensive rats.

[1]  A. Giordano,et al.  Antisense inhibitory effect: A comparison between 3′‐partial and full phosphorothioate antisense oligonucleotides , 1999, Journal of cellular biochemistry.

[2]  J. Summerton,et al.  A specificity comparison of four antisense types: morpholino, 2'-O-methyl RNA, DNA, and phosphorothioate DNA. , 1997, Antisense & nucleic acid drug development.

[3]  D. Chadwick,et al.  Oligonucleotides as therapeutic agents , 1997 .

[4]  U. Galderisi,et al.  Myotonic dystrophy: antisense oligonucleotide inhibition of DMPK gene expression in vitro. , 1996, Biochemical and biophysical research communications.

[5]  C. Stein,et al.  Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix (*) , 1995, The Journal of Biological Chemistry.

[6]  D. Wielbo,et al.  Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin , 1993, Regulatory Peptides.

[7]  S. Crooke.  Therapeutic applications of oligonucleotides. , 1992, Bio/technology.

[8]  P. Timmermans,et al.  Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). , 1990, The Journal of pharmacology and experimental therapeutics.

[9]  R. Tallarida,et al.  Manual of Pharmacologic Calculations: With Computer Programs , 1984 .